These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Photodynamic therapy for steroid-associated central serous chorioretinopathy. Lee TG; Kim JE Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080 [TBL] [Abstract][Full Text] [Related]
23. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
25. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387 [TBL] [Abstract][Full Text] [Related]
26. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y Retina; 2010; 30(10):1698-703. PubMed ID: 20539254 [TBL] [Abstract][Full Text] [Related]
27. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Fujita K; Yuzawa M; Mori R Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236 [TBL] [Abstract][Full Text] [Related]
28. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089 [TBL] [Abstract][Full Text] [Related]
30. Morphological and Functional Changes Immediately After Half-Time Photodynamic Therapy in Patients With Central Serous Chorioretinopathy. Muslubas IS; Ersoz MG; Hocaoglu M; Arf S; Karacorlu M Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):932-940. PubMed ID: 30566700 [TBL] [Abstract][Full Text] [Related]
31. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Rouvas A; Stavrakas P; Theodossiadis PG; Stamatiou P; Milia M; Giannakaki E; Datseris I Eur J Ophthalmol; 2012; 22(3):417-22. PubMed ID: 21928269 [TBL] [Abstract][Full Text] [Related]
32. The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy. Jirarattanasopa P; Ratanasukon M; Bhurayanontachai P J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S56-60. PubMed ID: 22696853 [TBL] [Abstract][Full Text] [Related]
33. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF; Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758 [TBL] [Abstract][Full Text] [Related]
34. Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy. Casalino G; Del Turco C; Corvi F; Rafaeli O; Bandello F; Querques G Ophthalmic Res; 2016; 56(1):23-9. PubMed ID: 27003789 [TBL] [Abstract][Full Text] [Related]
35. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824 [TBL] [Abstract][Full Text] [Related]
36. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Chan WM; Lai TY; Lai RY; Liu DT; Lam DS Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401 [TBL] [Abstract][Full Text] [Related]
37. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy. Chung CY; Chan YY; Li KKW Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395 [TBL] [Abstract][Full Text] [Related]
38. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046 [TBL] [Abstract][Full Text] [Related]
39. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy]. Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817 [TBL] [Abstract][Full Text] [Related]
40. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]